AstraZeneca’s AZN fourth-quarter 2024 core earnings of $1.05 per American depositary share (“ADS”) missed the Zacks Consensus ...

In addition to revenue growth, AstraZeneca's core earnings per share climbed 44% to $2.09. Research and development spending ...

CEO Guido Oelkers highlighted an 8% growth in Q4 revenues, driven primarily by hematology sales, and an adjusted EBITDA margin of 34%. He noted strong demand for Altuvoct and Vonjo, with Altuvoct ...

Shares of Swedish Orphan Biovitrum AB (STO:SOBI) fell 3% as the company's fourth-quarter earnings report revealed mixed results. While overall Q4 revenue met consensus expectations, sales of its key ...

Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter 2024. Fourth Quarter 2024 Total revenue increased ...

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of 10.3% at CER 1and business EPS 2of €1.

Eric Le Berrigaud, an analyst from Stifel Nicolaus, maintained the Buy rating on Sanofi (SNYNF – Research Report). The associated price target ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

More than 86,000 recorded cases of respiratory syncytial virus in 2024 were in children younger than four years old.

Q4 earnings for companies such as Johnson & Johnson, Teva, and Roche highlight the impact of significant innovations brought ...

Q4 guidance included expanded metrics for 2025, such as mid to high single-digit sales growth and low double-digit EPS growth, compared to a more cautious outlook in Q3. Management also introduced a ...